Related Experiment Video
Updated: Dec 28, 2025

Following in Real Time the Impact of Pneumococcal Virulence Factors in an Acute Mouse Pneumonia Model Using Bioluminescent Bacteria
Published on: February 23, 2014
Human Metapneumovirus: A Largely Unrecognized Threat to Human Health
Charles J Russell1,2, Rhiannon R Penkert1, Sonnie Kim3
1Department of Infectious Diseases, St. Jude Children's Research Hospital, Memphis, TN 38105, USA.
Insights
Human metapneumovirus (HMPV) is a common childhood respiratory virus with no current vaccine or treatment. Increased awareness is crucial for developing interventions and preventing severe illness in vulnerable populations.
Area of Science:
- Virology
- Public Health
- Immunology
Background:
- Human metapneumovirus (HMPV) is a significant respiratory pathogen.
- Infection is nearly universal in children by age five.
- HMPV poses a serious threat to young children and the elderly.
Purpose of the Study:
- To highlight the public health impact of HMPV.
- To emphasize the need for HMPV vaccine development.
- To underscore the urgency for HMPV treatment research.
Main Methods:
- Literature review on HMPV epidemiology and disease burden.
- Analysis of current therapeutic and vaccine development landscape.
- Assessment of public health implications and research priorities.
Main Results:
- HMPV causes substantial upper and lower respiratory tract disease.
- High-risk groups include infants, young children, and the elderly.
- No licensed vaccines or standard treatments are currently available for HMPV.
Conclusions:
- There is a critical need for increased awareness of HMPV's impact.
- Accelerated research is required to complete vaccine development.
- Preventing HMPV-associated morbidity and mortality necessitates a concerted global effort.
Abstract:
Human metapneumovirus (HMPV) infects most children by five years of age. The virus can cause both upper and lower respiratory tract disease and can be life threatening. High-risk populations include young children who are exposed to virus for the first time and the elderly. Currently, there is no standard treatment nor licensed vaccine for HMPV, although several attractive vaccine candidates have been developed for pre-clinical studies. A raised awareness of the impact of HMPV on public health is needed to drive research, complete vaccine development, and thereby prevent significant virus-associated morbidities and mortalities worldwide.
Related Concept Videos
Pneumonia I: Introduction
Risk Factors
Various factors influence the likelihood of developing pneumonia. Age plays a crucial role, with infants, children under two, and individuals over 65 at increased risk due to their...
Viral Recombination
Pneumonia V: Nursing management and Prevention
The nurse must practice strict medical asepsis and adhere to infection control guidelines to minimize healthcare-associated infections.
Enhance airway patency
Position the patient correctly to facilitate drainage of the affected lung segments. Manual or mechanical percussion and vibration can also be employed....
Pneumonia II: Pathophysiology
Transmission-based Precautions II: Airborne and Protective Environment
Airborne precautions:
Use airborne precautions when treating patients known or suspected to have diseases that spread through the air—for example, tuberculosis or measles. These organisms are present in smaller droplets expelled by an infected person and...
Viral Mutations

